Endocrine Abstracts

In acromegalic patients not suitable for first-line surgical treatment, pharmacotherapy is a valuable choice. Depot somatostatin analogs (SSA) represent efficacious and well-tolerated drugs; however, they normalize hormonal parameters in no more than 65–75%. Pegvisomant (PEGA), a GH receptor antagonist, has been shown to normalize IGF-I levels in more than 90% of patients. We report our experience in 13 acromegalic patients (7 M, 6 F; age: 50.2±3.9 yrs; 7 macroadenom...